Introduction
Prostate cancer is the second most common and fifth most aggressive cancer among men worldwide.1 According to one estimate, 1 in 7 US men and 1 in 25 men worldwide will be diagnosed with prostate cancer during his lifetime.1 Despite the advanced screening methods available, such as measurement of prostate-specific antigen levels, the incidence of metastatic disease remains as high as 20%.2 The best-known risk factors for prostate cancer are race (ie, African American descent), obesity, and genetics (eg, BRCA1/2 mutations). Gleason scoring is commonly used for histopathologic evaluation and for clinical and pathologic staging of disease. Patients with high-risk disease are treated with prostatectomy and/or external beam radiotherapy followed by androgen deprivation therapy (ADT) as maintenance therapy. If disease progression occurs while the patient is receiving ADT, the disease is noted to be castration-resistant prostate cancer (CRPC). Unfortunately, the majority of patients with prostate cancer progress to castration-resistant disease within 2 to 3 years.3
For decades the standard-of-care (SOC) treatment for metastatic CRPC (mCRPC) has been composed of cytotoxic agents, including taxanes (docetaxel or cabazitaxel [Jevtana]), and second-generation antihormonal agents (antihormonal therapy; AHT) such as abiraterone (Zytiga) or enzalutamide (Xtandi). Previously, CRPC was called androgen-independent prostate cancer and hormone-refractory prostate cancer.4 Subsequently, results of several studies showed that intratumoral (intracrine and paracrine) androgen production plays a significant role in the development of resistance among prostate cancer cells to testosterone suppression therapy.5
Other treatment options include pembrolizumab (Keytruda) for PD-L1positive and microsatellite instability (MSI)high disease, and radium-223 (Xofigo) for bone metastasis. PARP1 (or PARP) inhibitors are used in patients with mutations in homologous recombination repair (HRR) genes (most commonly, BRCA1/2). Recent study results indicate that the androgen receptor (AR) regulates the DNA repair pathways, and reciprocally, several enzymes involved in DNA repair can moderate AR activity.6-8 An example of such an enzyme is PARP1, which is involved in identifying single-stranded DNA breaks and their repair through the base excision method.9 Several cancers, including prostate cancer, exhibit increased PARP1 activity or expression.9-11 The mechanism of action of PARP inhibitors includes physical obstruction of the replication fork (PARP trapping), which affects HRR, resulting in DNA double-strand breaks.12 Previous study results have shown that these PARP inhibitors are synergistic when used with agents affecting the AR pathway regardless of HRR mutation status.9,13 In 2020, for the first time, the FDA approved PARP inhibitors for use in mCRPC.
The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
The authors followed PRISMA guidelines.
The databases accessed were Cochrane Central Registry of Clinical Trials, Embase, and PubMed. Search terms used were PARP inhibitors, prostate cancer, prostate neoplasm, olaparib (Lynparza), veliparib.
Papers had no restrictions in terms of date or status ofpublications. To be included, however, the papers had to report on RCTs that:
1. compared PARP inhibitors against SOC in patients with mCRPC;
2. reported PFS and OS;
3. included only patients 18 years or older; and
4. were available in the English language.
Papers that did not meet the above criteria were excluded.
Three authors independently reviewed all articles and abstracts and excluded the irrelevant trials. Risk of bias for selected papers was assessed using the Cochrane Collaboration tool and then classified as high, uncertain, or low.
Information was extracted using a prespecified extraction table. Information was extracted from the papers by reading through the main texts and tables, and a second author reviewed the information collected to ensure its accuracy. The extracted data included HRs for PFS and OS.
The meta-analysis was performed using Comprehensive Meta-analysis software version 3. HRs were calculated for PFS and OS . For effect sizes, a 95% CI was used, and a P value of less than .05 indicated statistical significance. Analysis was done using random and fixed models and both were reported. Heterogeneity was evaluated using I2 statistic and categorized as low (<40), moderate (40-60), and high (>60). Where a median was used, it was assumed to be equivalent to the mean, and SDs were estimated by dividing interquartile differences by 1.35. Fixed effectanalysis is usually adapted in cases where I2 value is 50%; otherwise, random effect model is used.
The initial search identified 351 articles; removal of duplicates left 322. The first screening excluded 262 articles. The full texts of the remaining 60 articles were analyzed. Thirty-seven articles were excluded because the trials described were incomplete; 13 were review articles; 2 described trials that were terminated; 4 were about single-arm studies; and 1 articles study did not have relevant intervention. Ultimately, articles describing 3 RCTs were included, and these trials had a total of 682 patients. The PRISMA flow diagram is shown in Figure 1, and main characteristics of RCTs are listed in the Table.
Risk of bias
The results of risk of bias are shown in Figure 2 and Figure 3.
Overall survival
Two studies reported OS when patients usedPARP inhibitors compared with SOC.14,15 The difference was statistically significant when calculated using the fixed model (HR, 0.751; 95% CI, 5.82-0.968; P = .027), and I2 = 23.23. When calculated using the random model, there was a strong deviation favoringPARP inhibitors,but it did not reach statistical significance (HR, 0.758; 95% CI, 0.565-1.017; P = .064)(Figure 4).
Progression-free survival
Three studies reported PFS when patients usedPARP inhibitorscompared with SOC.14-16 The difference was statistically significant when calculated using the fixed model (HR, 0.626; 95% CI, 0.521-0.752; P <.001), and I2 = 80.240. When calculated using the random model, there was a strong deviation favoringPARP inhibitors, but it did not reach statistical significance (HR, 0.674; 95% CI, 0.437-1.039; P = .074)(Figure 5).
Overall results of this meta-analysis indicate that patients with mCRPC experience survival benefits when treated with PARP inhibitors as compared with placebo or SOC chemotherapy. OS was better in the PARP inhibitor group under fixed effect (HR, 0.751; 95% CI,0.582-0.968; P = .027) and under random effect (HR, 0.758; 95% CI, 0.565-1.017; P = .064). PFS was improved in the PARP inhibitor group (HR, 0.626; 95% CI, 0.521-0.752; P <.001) compared with the chemotherapy group when analyzed under fixed effect.
In 2020, the FDA approved 2 PARP inhibitorsrucaparib (Rubraca) and olaparibto treat mCRPC in patients harboring somatic and/or germline mutations in BRCA1 or BRCA2 as well as in ATM genes. This decision was based upon the data from the multicenter, single-arm TRITON2 clinical trial (NCT02952534), in which rucaparib was used in patients with mCRPC positive for BRCA mutations. Currently, numerous clinical trials are ongoing to determine the efficacy of PARP inhibitors in mCRPC. Ongoing clinical trials with olaparib, veliparib, rucaparib, niraparib (Zejula), and talazoparib (Talzenna) in mCRPC were searched on the clinicaltrials.gov website. Currently, 37 trials are ongoing, 2 have been terminated, and 3 trials have been completed.
In 2 trials, olaparib was the study drug.14,15 In Clarke et al, patients were randomized into the treatment group (abiraterone plus olaparib) or the control group (abiraterone alone) irrespective of any genetic mutations or biomarker criteria. The study showed statistically significant improvement in both PFS and OS in the treatment group, indicating that a broader population, regardless of HRR mutation status, can benefit from the synergy of PARP inhibitors and AR inhibitors. However, men with HRR mutations derive the greatest benefit from these medications.
Our literature review also shows that PARP inhibitors are much more effective in patients with HRR or ATM mutations. In the PROfound study (NCT02987543; de Bono et al), patients were divided into 2 cohorts: Cohort A included patients with 1 or more of 3 mutations (BRCA1/2; ATM), and Cohort B included patients with a mutation in any of 12 other prespecified genes. Each cohort was divided into a treatment arm (olaparib) and a control arm (enzalutamide or abiraterone). OS was prolonged when measured together for cohorts A and B: 17.5 months with PARP inhibitor vs 14.4 months with chemotherapy (HR for death, 0.67; 95% CI, 0.49-0.93). The PFS for cohort A vs cohort B was 7.4 months vs 3.6 months, respectively; HR for progression or death, 0.34; 95% CI, 0.25-0.47; P < .001. The results for Cohort A and B combined showed median PFS to be 5.8 months vs 3.5 months (HR, 0.49; 95% CI, 0.38-0.63; P <.001). Once again, these results indicate that PARP inhibitors are effective in patients with mCRPC regardless of genetic mutation status, although responses are much more evident in the population with BRCA and ATM alterations.
In the third trial (NCT01576172; Hussain et al), veliparib was compared with a control regimen of abiraterone plus prednisone.16 The investigators primary objective was to see if ETS fusion status (related to a family of transcription factors) has a role in the tumor response to the treatment. Patients were first divided according to ETS fusion status (positive or negative) and then equally distributed in the case and control cohorts. Surprisingly, there was no difference in PFS between the treatment arms, regardless of ETS status, with overall PFS of 11 months (95% CI, 8.1-13.6) in the treatment group vs 10.1 months (95% CI, 8.2-13.8) in the control group (P = .99). However, a significant finding was that DNA repair status (ie, DRD gene mutation) was associated with statistically significant improvement in PFS regardless of treatment status: 14.5 months (abnormal DRD gene) vs 8 months (normal DRD gene) (HR, 0.52; 95% CI, 0.29-0.93; P = .02). This study was not included in the forest plot for OS because OS was not calculated in this group.
This study, as a meta-analysis, remains a retrospective chart review; the possibility for biases exists. Fewer trials and smaller study populations lead to publication bias. We made our best effort to locate all relevant published studies, randomize them, and complete data extraction and analysis. Another major limitation of this trial is the difficulty in performing stratified pool analysis for each PARP inhibitor drug; only a very limited number of completed phase 2/3 RCTs have currently available results. Other potential contributors to bias for this meta-analysis include heterogeneous population and inclusion criteria (with different first-line therapy patients and BRCA or other gene mutations). Another limitation is the inability to compare the adverse effect profiles between the PARP inhibitor and chemotherapy groups.
Conversely, a strength of this analysis is that it includes all phase 2/3 RCTs evaluating the efficacy of PARP inhibitors in mCRPC that have been completed and published, to date.
This meta-analysis shows that PARP inhibitors can prolong PFS or OS compared to SOC treatment in patients with mCRPC irrespective of HRR or other genetic mutation status. Longer PFS and OS were seen when PARP inhibitors were used alone or in combination with AHT therapies like abiraterone or enzalutamide. The effect was more significant when examined with a fixed model analysis. Although there was a significant deviation towards an increase in PFS and OS in the random model analysis, the effect was not statistically significant, and it was likely secondary to a relatively small patient population in the meta-analysis. Although, at baseline, there was heterogeneity among the populations participating in these trials, in terms of genetic alterations, the results of all the trials showed better outcomes in their intervention arms. This heterogeneity can be dealt with by incorporating more RCTs into meta-analyses going forward. More studies can further magnify these results once they are published.
DECLARATIONS
Ethics Approval and Consent to Participate: The data extracted and manuscript were reviewed with the Research Department and Ethics Committee of Department of Medicine, Staten Island University Hospital/Northwell. No experimental intervention was performed, and no specifications of guidelines, legislations, or permissions were required.
Availability of data and materials: Data are available in Excel files. Patient identifying information was removed at all stages in all the studies included.
Competing interests: No competing financial or personal interests are involved for all the authors.
Funding: No funding was obtained from any organization or personnel during any stage of manuscript writing or submission.
Authors contributions: Manuscript written and data obtained by M.R.K.N, A.J, S.S, S.B.S. Proofreading and literature review done by D.A and A.B.
AUTHOR AFFILIATIONS:
1. Department of Internal Medicine, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, USA.
2. Division of Hematology and Medical Oncology, Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, USA.
1. Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, staging and management of prostate cancer. Med Sci (Basel). 2020;8(3):28. doi:10.3390/medsci8030028
2. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22(20):4109-4118. doi:10.1200/jco.2004.11.514
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85. doi:10.1038/ncpuro1296
4. Ahmad K. New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol. 2004;5(12):706. doi:10.1016/s1470-2045(04)01641-9
5. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454. doi:10.1158/0008-5472.Can-08-0249
6. Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668-675. doi:10.1038/ng.613
7. Schiewer MJ, Knudsen KE. Linking DNA damage and hormone signaling pathways in cancer. Trends Endocrinol Metab. 2016;27(4):216-225 .doi:10.1016/j.tem.2016.02.004
8. Ta HQ, Gioeli D. The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocr Relat Cancer. 2014;21(5):R395-R407. doi:10.1530/erc-14-0217
9. Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134-1149. doi:10.1158/2159-8290.Cd-12-0120
10. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983;43(7):3441-3446.
11. Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell -diagnostic cytological usefulness. Cancer Lett. 1981;14(3):227-236. doi:10.1016/0304-3835(81)90148-8
12. OConnor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560. doi:10.1016/j.molcel.2015.10.040
13. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374. doi:10.1038/s41467-017-00393-y
14. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440
15. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(7):975-986. doi:10.1016/s1470-2045(18)30365-6
16. Hussain M, Daignault-Newton S, Twardowski PW, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36(10):991-999. doi:10.1200/jco.2017.75.7310
Read the original post:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled...
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]